reports
Sarepta Therapeutics Inc: 2 directors
Two Directors at Sarepta Therapeutics Inc sold/sold after exercising options 50,714 shares at between 161.615USD and 163.128USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
Liberty Latin America Ltd: 1 director
A director at Liberty Latin America Ltd bought 400,000 shares at 8.944USD and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- Jonathan Moreland
PAYC PAYCOM SOFTWARE INC.
ITCI INTRA-CELLULAR THERAPIES INC.
CTRN CITI TRENDS INC.
RDI READING INTERNATIONAL INC.
AFB ALLIANCEBERNSTEIN NATIONAL MUNICIPAL INCOME FUND
NHF NEXPOINT CREDIT STRATEGIES FUN
NINE NINE ENERGY SERVICE INC
LILA LIBERTY LATIN AMERICA A
MCFT MASTERCRAFT BOAT HOLDINGS
HQL TEKLA LIFE SCIENCES INVESTORS
ATHA ATHIRA PHARMA
NUVB NUVATION BIO INC (A)
PX P10 INC
PROK PROKIDNEY CORP.
GNT GABELLI NATURAL RESOURCES
PEO GOLD AND INCOME TRUST
DMA PETROLEUM & RESOURCES CORPORATION
NRBO DESTRA MULTI ALTERNATIVE FUND
NEUROBO PHARMACEUTICALS INC
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Rotation is the Lifeblood of a Bull Market Semiconductors (SMH, SOXX, NVDA, AVGO, etc.) have been leadership since late-2022, but they are extended and are starting to see some profit taking as market participants rotate into other areas of the market that have been lagging (especially Energy, and to a lesser extent banks and small-caps). The question is whether this new trend lasts a few days, or if this is the start of longer-term trend. We would not be surprised to see more consolidation for...
WM WASTE MANAGEMENT INC.
TTEK TETRA TECH INC.
TJX TJX COMPANIES INC
ROST ROSS STORES INC.
ROL ROLLINS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
ITCI INTRA-CELLULAR THERAPIES INC.
HALO HALOZYME THERAPEUTICS INC.
CLH CLEAN HARBORS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
IONS IONIS PHARMACEUTICALS INC.
RSG REPUBLIC SERVICES INC.
UTHR UNITED THERAPEUTICS CORPORATION
WCN WASTE CONNECTIONS INC.
MDGL MADRIGAL PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
PCVX VAXCYTE
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SRPT SAREPTA THERAPEUTICS INC.
SPR SPIRIT AEROSYSTEMS HOLDINGS INC. CLASS A
MNKD MANNKIND CORP.
BCRX BIOCRYST PHARMACEUTICALS INC.
ALNY ALNYLAM PHARMACEUTICALS INC
AGIO AGIOS PHARMACEUTICALS INC.
RY4C RYANAIR HOLDINGS PLC
LILA LIBERTY LATIN AMERICA A
DNLI DENALI THERAPEUTICS INC
ADT ADT INC
HROW HARROW HEALTH INC.
TWST TWIST BIOSCIENCE
DYN DYNE THERAPEUTICS
SMLP SUMMIT MIDSTREAM PARTNERS
RNA AVIDITY BIOSCIENCES
TNGX TANGO THERAPEUTICS INC
RYAN RYAN SPECIALTY GROUP HLDGS INC
RKLB ROCKET LAB USA INC
BTMD HAYMAKER ACQUISITION CORP III
IBRX IMMUNITYBIO INC
CDRO CODERE ONLINE LUXEMBOURG SA
XPOF XPONENTIAL FITNESS INC
UBXG U BX TECHNOLOGY LTD
FTLF FITLIFE BRANDS INC.
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Pote...
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central ner...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
URI UNITED RENTALS INC.
SIX SIX FLAGS ENTERTAINMENT CORPORATION
FTH SILESIA ONE SA
WWW WOLVERINE WORLD WIDE INC.
WING WINGSTOP INC.
NVDA NVIDIA CORPORATION
MU MICRON TECHNOLOGY INC.
MPWR MONOLITHIC POWER SYSTEMS INC.
LOCO EL POLLO LOCO HOLDINGS INC
LMAT LEMAITRE VASCULAR INC.
LAKE LAKELAND INDUSTRIES INC.
GPRK GEOPARK
GLW CORNING INC
FUN CEDAR FAIR L.P.
CNK CINEMARK HOLDINGS INC.
BPMC BLUEPRINT MEDICINES CORP.
AOSL ALPHA & OMEGA SEMICONDUCTOR
EGY VAALCO ENERGY INC.
MEG. MEG ENERGY CORP.
CW CURTISS-WRIGHT CORPORATION
LZB LAZBOY INCORPORATED
CAH CARDINAL HEALTH INC.
FI FRANK'S INTERNATIONAL NV
NSA NATIONAL STORAGE AFFILIATES TRUST
ELF E.L.F. BEAUTY INC.
AMKR AMKOR TECHNOLOGY INC.
DELL DELL TECHNOLOGIES INC CLASS C
TWST TWIST BIOSCIENCE
DYN DYNE THERAPEUTICS
VRT VERTIV HOLDINGS CO (A)
SG SWEETGREEN INC
FTAI ONTO INNOVATION INC.
RDW FORTRESS TRANSN & INFRAS INVS LLC
2VZ REDWIRE CORP
FIP LEONARDO DRS INC.
FTAI INFRASTRUCTURE INC
ADT Appoints Dan Houston and Danielle Tiedt to the Company’s Board of ...
ADT Appoints Dan Houston and Danielle Tiedt to the Company’s Board of Directors BOCA RATON, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- (NYSE: ADT), the most trusted brand in smart home and small business security, today announced the appointment of Dan Houston and Danielle Tiedt to the Company’s Board of Directors as additional independent directors. In conjunction with their appointments, Houston and Tiedt will both join the Board’s Nominating and Corporate Governance Committee, while Houston will also join the Board’s Compensation Committee. “We are pleased to welcome Dan and Danielle ...
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapiv...
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress – ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time or 4 p.m. Central European S...
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohu...
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress - Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today highlighted new preclinical data for DYNE-302, its product candidat...
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global...
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the time of the company’s presentation at the Goldman Sachs 45th Annual Global Healthcare Conference has been updated to Monday, June 10, 2024 at 8:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors sect...
Agios Pharmaceuticals Inc: 1 director
A director at Agios Pharmaceuticals Inc sold 1,362 shares at 44.390USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- Carole Braudeau
- Carole Braudeau
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 74,875 shares, and restricted stock units (RSUs) covering an aggregate of 39,050 shares, of BioCryst common stock. The options and RSUs were granted as of May 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in ...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for M...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseasesDNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potential for clinical benefit for a rare neurodegenerative disease and the drug sponsor’s ability to advance development tow...
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endp...
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia – Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key Secondary Endpoints Evaluating Additional Measures of Reduction of Transfusion Burden Compared to Placebo – – ENERGIZE-T is the First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Depe...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
APLE APPLE HOSPITALITY REIT INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
CVNA CARVANA CO. CLASS A
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
PRAX PRAXIS PRECISION MEDICINES
COGT COGENT BIOSCIENCES INC
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
IKNA INC.
TCRX IKENA ONCOLOGY INC
DSGN TSCAN THERAPEUTICS INC
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
GMTX AEROVATE THERAPEUTICS INC
S GEMINI THERAPEUTICS INC
RLYB SENTINELONE INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
PEPG VIGIL NEUROSCIENCE INC
EWTX PEPGEN INC
NUVL EDGEWISE THERAPEUTICS INC
NUVALENT INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Liana Moussatos
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
BioCryst Presents New Real-world Evidence Showing Reductions in Attack...
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options RESEARCH TRIANGLE PARK, N.C., June 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.